Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02855827
Other study ID # P/2013/170
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 2013
Est. completion date October 2022

Study information

Verified date January 2021
Source Centre Hospitalier Universitaire de Besancon
Contact Chlotilde AMIOT, MD, PhD
Email camiot@chu-besancon.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Ovarian cryopreservation is one of the available option for preserving fertility prior to potentially sterilizing treatments. In the absence of other techniques such as in vitro folliculogenesis or injection of isolated ovarian follicles, this tissue can only be re-used by autograft. In France, the first live birth after orthotopic ovarian transplantation, was obtained by Roux et al. in 2009. This clinical trial aims to build a cohort of patients likely to use their ovarian tissue cryopreserved by autograft.


Description:

Ovarian cryopreservation is one of the available option for preserving fertility prior to potentially sterilizing treatments. In the absence of other techniques such as in vitro folliculogenesis or injection of isolated ovarian follicles, this tissue can only be re-used by autograft. In France, the first live birth after orthotopic ovarian transplantation, was obtained by Roux et al. in 2009. This clinical trial aims to build a cohort of patients likely to use their ovarian tissue cryopreserved by autograft. This cohort will be used to: - Follow up of patients with their cryopreserved ovarian tissue; - Evaluate requests for ovarian tissue grafting ; - Propose a search of residual disease in case of neoplastic disease risk (if possible); - Allowing patients to benefit from an ovarian tissue autograft; - Assess the effectiveness of autograft technique after the restoration of ovarian function.


Read more »

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France CHRU Besancon Besançon

Sponsors (10)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Besancon Central Hospital, Nancy, France, CHU de Reims, CMCO SIHCUS, Schiltingheim, Nantes University Hospital, University Hospital, Bordeaux, University Hospital, Grenoble, University Hospital, Lille, University Hospital, Limoges, University Hospital, Marseille

Country where clinical trial is conducted

France, 

References & Publications (3)

Amiot C, Angelot-Delettre F, Zver T, Alvergnas-Vieille M, Saas P, Garnache-Ottou F, Roux C. Minimal residual disease detection of leukemic cells in ovarian cortex by eight-color flow cytometry. Hum Reprod. 2013 Aug;28(8):2157-67. doi: 10.1093/humrep/det126. Epub 2013 Apr 30. — View Citation

Fauque P, Ben Amor A, Joanne C, Agnani G, Bresson JL, Roux C. Use of trypan blue staining to assess the quality of ovarian cryopreservation. Fertil Steril. 2007 May;87(5):1200-7. Epub 2007 Feb 20. — View Citation

Roux C, Amiot C, Agnani G, Aubard Y, Rohrlich PS, Piver P. Live birth after ovarian tissue autograft in a patient with sickle cell disease treated by allogeneic bone marrow transplantation. Fertil Steril. 2010 May 1;93(7):2413.e15-9. doi: 10.1016/j.fertnstert.2009.12.022. Epub 2010 Feb 1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patient who are candidate to ovarian tissue autograft 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT02846064 - Development of Ovarian Tissue Autograft in Order to Restore Ovarian Function N/A
Unknown status NCT01782807 - Ovarian Function After Hysterectomy With or Without Fimbriectomy or Salpingectomy N/A
Completed NCT00429494 - GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients Phase 2
Recruiting NCT05330130 - Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa Cells Phase 1
Completed NCT05489367 - Does COVİD-19 m-RNA Vaccine Affect Fertility and Over Reserve ?